Literature DB >> 21836537

Survival determinants in lung transplant patients with chronic allograft dysfunction.

Geert M Verleden1, Robin Vos, Stijn E Verleden, Walter De Wever, Stéphanie I De Vleeschauwer, Anna Willems-Widyastuti, Hans Scheers, Lieven J Dupont, Dirk E Van Raemdonck, Bart M Vanaudenaerde.   

Abstract

BACKGROUND: Chronic lung allograft dysfunction (CLAD) remains the leading cause of mortality after lung transplantation.
METHODS: In this retrospective single-center study, we aimed to identify different phenotypes of and risk factors for mortality after CLAD diagnosis using univariate and multivariate Cox proportional hazard survival regression analysis.
RESULTS: CLAD was diagnosed in 71 of 294 patients (24.2%) at 30.9±22.8 months after transplantation. Pulmonary function was obstructive in 51 (71.8%) of the CLAD patients, restrictive in 20 (28.2%) patients, of whom 17 had persistent parenchymal infiltrates on pulmonary computer tomography (CAT) scan. In univariate analysis, previous development of neutrophilic reversible allograft dysfunction (NRAD, P=0.012) and a restrictive pulmonary function (P=0.0024) were associated with a worse survival, whereas there was a strong trend for early development of CLAD and persistent parenchymal infiltrates on CAT scan (P=0.067 and 0.056, respectively). In multivariate analysis, early development of CLAD (P=0.0067), previous development of NRAD (P=0.0016), and a restrictive pulmonary function pattern (P=0.0005) or persistent parenchymal infiltrates on CAT scan (P=0.0043) remained significant.
CONCLUSION: Although most CLAD patients develop an obstructive pulmonary function, 28% develop a restrictive pulmonary function, compatible with the recently defined restrictive allograft syndrome phenotype. Early-onset CLAD, previous development of NRAD, and the development of restrictive allograft syndrome are associated with worse survival after CLAD has been diagnosed.

Entities:  

Mesh:

Year:  2011        PMID: 21836537     DOI: 10.1097/TP.0b013e31822bf790

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  23 in total

1.  Voriconazole Exposure and Risk of Cutaneous Squamous Cell Carcinoma, Aspergillus Colonization, Invasive Aspergillosis and Death in Lung Transplant Recipients.

Authors:  M Mansh; M Binstock; K Williams; F Hafeez; J Kim; D Glidden; R Boettger; S Hays; J Kukreja; J Golden; M M Asgari; P Chin-Hong; J P Singer; S T Arron
Journal:  Am J Transplant       Date:  2015-09-03       Impact factor: 8.086

2.  Bronchiolitis obliterans syndrome-free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis.

Authors:  Hrishikesh S Kulkarni; Wida S Cherikh; Daniel C Chambers; Victoria C Garcia; Ramsey R Hachem; Daniel Kreisel; Varun Puri; Benjamin D Kozower; Derek E Byers; Chad A Witt; Jennifer Alexander-Brett; Patrick R Aguilar; Laneshia K Tague; Yuka Furuya; G Alec Patterson; Elbert P Trulock; Roger D Yusen
Journal:  J Heart Lung Transplant       Date:  2018-09-25       Impact factor: 10.247

3.  Restrictive allograft syndrome after lung transplantation: new radiological insights.

Authors:  Adriana Dubbeldam; Caroline Barthels; Johan Coolen; Johny A Verschakelen; Stijn E Verleden; Robin Vos; Geert M Verleden; Walter De Wever
Journal:  Eur Radiol       Date:  2016-11-22       Impact factor: 5.315

4.  Fibroproliferation in chronic lung allograft dysfunction: Association of mesenchymal cells in bronchoalveolar lavage with phenotypes and survival.

Authors:  Michael P Combs; Meng Xia; David S Wheeler; Elizabeth A Belloli; Natalie M Walker; Russell R Braeuer; Dennis M Lyu; Susan Murray; Vibha N Lama
Journal:  J Heart Lung Transplant       Date:  2020-04-19       Impact factor: 10.247

Review 5.  Lung transplantation: a treatment option in end-stage lung disease.

Authors:  Marc Hartert; Omer Senbaklavacin; Bernhard Gohrbandt; Berthold M Fischer; Roland Buhl; Christian-Friedrich Vahld
Journal:  Dtsch Arztebl Int       Date:  2014-02-14       Impact factor: 5.594

6.  Update on Chronic Lung Allograft Dysfunction.

Authors:  Jason M Gauthier; Ramsey R Hachem; Daniel Kreisel
Journal:  Curr Transplant Rep       Date:  2016-08-02

Review 7.  Chronic lung allograft dysfunction phenotypes and treatment.

Authors:  Stijn E Verleden; Robin Vos; Bart M Vanaudenaerde; Geert M Verleden
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

Review 8.  Detection, classification, and management of rejection after lung transplantation.

Authors:  Amit D Parulekar; Christina C Kao
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

9.  Impact of CLAD Phenotype on Survival After Lung Retransplantation: A Multicenter Study.

Authors:  S E Verleden; J L Todd; M Sato; S M Palmer; T Martinu; E N Pavlisko; R Vos; A Neyrinck; D Van Raemdonck; T Saito; H Oishi; S Keshavjee; M Greer; G Warnecke; J Gottlieb; A Haverich
Journal:  Am J Transplant       Date:  2015-04-30       Impact factor: 8.086

10.  Impact of forced vital capacity loss on survival after the onset of chronic lung allograft dysfunction.

Authors:  Jamie L Todd; Rahil Jain; Elizabeth N Pavlisko; C Ashley Finlen Copeland; John M Reynolds; Laurie D Snyder; Scott M Palmer
Journal:  Am J Respir Crit Care Med       Date:  2014-01-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.